Guggenheim Issues Positive Forecast for Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Price

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) had its price objective upped by stock analysts at Guggenheim from $40.00 to $60.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s price objective suggests a potential upside of 196.00% from the stock’s previous close.

Several other research firms have also recently weighed in on DMRA. TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, September 14th. Jefferies Financial Group initiated coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They issued a “buy” rating and a $50.00 target price for the company. Wedbush raised their price target on Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Thursday, July 30th. Finally, HC Wainwright reissued a “buy” rating and set a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $46.50.

Damora Therapeutics, Inc. Common Stock Stock Down 0.8%

Damora Therapeutics, Inc. Common Stock stock opened at $20.27 on Friday. The stock has a 50-day simple moving average of $28.64 and a 200 day simple moving average of $26.38. Damora Therapeutics, Inc. Common Stock has a 12-month low of $3.50 and a 12-month high of $38.33. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -6.01 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.06. As a group, sell-side analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current year.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

A number of institutional investors have recently made changes to their positions in the stock. Braidwell LP bought a new position in Damora Therapeutics, Inc. Common Stock during the second quarter worth about $42,146,000. Seven Fleet Capital Management LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $7,398,000. Squarepoint Ops LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at approximately $303,000. Finally, Arizona State Retirement System bought a new position in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $260,000. 14.20% of the stock is owned by institutional investors and hedge funds.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.